Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Biocytogen Signs BiSpecific ADC Discovery Deal with Korea’s ABL Bio

publication date: Mar 26, 2024

Biocytogen Pharma (Beijing) will collaborate with ABL Bio of Korea to develop new bispecific antibody-drug conjugates (bsADCs). ABL says it is the first Korean pharma to have started clinical trials of its own bispecific.  Biocytogen will use its RenLite® mice platform to produce fully human antibody candidates with diverse epitopes and high affinity. The company has signed 50 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and established 42 target-nominated RenMice® licensing projects globally. More details....

Stock Symbols: (HK: 02315) (KOSDAQ: 298380)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital